Expert panelâ€™s condition: Must submit Ph 1 results before starting Ph II trial of Covaxin
More than a fortnight before the Indian Council of Medical Research (ICMR) wrote to clinical trial sites that it was â€œenvisaged to launchâ€ the Covid-19 vaccine â€œfor public health use latest by 15th August 2020â€, an expert committee of Indiaâ€™s drugs regulator had laid down four specific conditions that the company developing the vaccine candidate would have to meet.
The Drugs Controller General of India (DCGI) permitted Phase I and II clinical trials of Covaxin, but a Subject Expert Committee (SEC), which evaluates applications for clinical trials, said that Hyderabad-based Bharat Biotech â€œshould submit results of the Phase I clinical trial to the DCGI before initiating the Phase-II studyâ€.
Also, the SEC recommended after its meeting held on June 15, â€œclinical trial sites should have facilities to handle emergency situations such as anaphylaxis (a severe allergic reaction)â€, and that â€œthe investigators should have appropriate qualification & experiences suitable for the conduct of the studyâ€.
Since healthy persons would be enrolled in the clinical trial, the SEC laid down that â€œRT-PCR test should be used as confirmatory test for Covid-19 during screeningâ€.
The SEC put these conditions after the company presented data on â€œsafetyâ€ and â€œimmunogenicityâ€ collected during pre-clinical trials conducted on rats, mice, and rabbits.
Experts said that these conditions, which are essential to the clinical trial, â€œwill resultâ€ in the trial taking longer than ICMRâ€™s unrealistic timeframe. The SEC set no deadlines.
Explained: ICMR claims it wants to launch Covaxin by August 15, hereâ€™s everything you need to know
An investigator who is part of the trial said â€œimmunogenicityâ€ â€“ the ability to provoke an immune reaction â€“ will be the key aspect to be examined, and which will decide if the trial can move from Phase I to II.
â€œEven with Covid-19, those with a mild infection donâ€™t have that many antibodies. What immune response we will get, is the key question. This process may take a few months. You have to examine if the vaccine is able to produce enough neutralising antibodies to fight the virus,â€ the investigator said.
â€œEven if the vaccine produces antibodies, we need to examine if they sustain for some time. The antibodies may last only for a few weeks. You canâ€™t have a vaccine that has to be given every few weeks,â€ the investigator said.
Referring to the first crucial condition â€“ on submitting the results of Phase I of the clinical trial â€“ put by the expert committee, another investigator said the first phase was likely to take â€œat least three monthsâ€.
â€œDiverse populations have to be enrolled,â€ this investigator said. â€œWe have to check if the vaccine is equally effective in the young, elderly, and people with comorbidities. There is no way this can be done in a month. Besides the analysis of the data, the recruitment for the first phase will go on till October.â€ The process â€œcannot be fast-trackedâ€, the investigator said.
	

â€œExamining the vaccinating-related side effects will be the most crucial. There is vaccine-related enhanced respiratory syndrome, where you have vaccine-led infections of lungs and airways that cause an immune reaction. Then, you have a reaction because of the vaccine, which enhances the infection. This happened during the development of the vaccines for HIV and measles. The vaccine produces antibodies that are not sufficient â€“ and they enhance the severity by allowing more of the virus to enter the cell,â€ he said.
ğŸ“£ The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines
